AIMS/HYPOTHESIS: We sought to understand the relationships between glycaemic status and both severity and progression of coronary artery disease (CAD), the leading cause of death in diabetes. METHODS: Baseline fasting blood glucose (FBG) and HbA1c (%)were measured in 426 patients with known or suspected stable CAD, who underwent coronary artery intravascular ultrasound(IVUS) at baseline and after a mean follow-up period of 664 days (range 257 to 961). The patients were categorised as normoglycaemic (n=226, 53%), or as having impaired fasting glucose (n=118, 28%) or diabetes (n=82, 19%). RESULTS: The maximum percentage coronary atheroma area at baseline was greater in diabetic patients (73.33+/-8.86%) than in those with normoglycaemia (69.08+/-10.43%; p=0.001) and impaired fasting glucose (69.32+/-9.59%; p=0.0031). In averaged IVUS measurements of the 30-mm target segment(n=332 participants), change in percentage atheroma area during follow-up was also greater in the diabetes (1.86+/-3.90%) than in other groups (0.28+/-3.32% and 0.56+/-2.96%,p=0.0047 global). FBG correlated with maximum percentage atheroma area at baseline (r=0.17; p=0.0003). HbA1c also correlated with maximum percentage atheroma area at baseline (r=0.26; p=0.0001) and with change in maximum plaque area (r=0.16; p=0.016). A similar pattern of results occurred with plaque volume. The relationships between diabetes or HbA1c and both IVUS measurements of plaque burden and remodelling persisted after adjustment. CONCLUSIONS/ INTERPRETATION: Fasting blood glucose, HbA1c and the presence of diabetes are associated with the severity and progression of coronary atherosclerosis. These observations support the hypothesis that better glycaemic control may favourably influence CAD in patients with abnormal glucose tolerance or diabetes.
AIMS/HYPOTHESIS: We sought to understand the relationships between glycaemic status and both severity and progression of coronary artery disease (CAD), the leading cause of death in diabetes. METHODS: Baseline fasting blood glucose (FBG) and HbA1c (%)were measured in 426 patients with known or suspected stable CAD, who underwent coronary artery intravascular ultrasound(IVUS) at baseline and after a mean follow-up period of 664 days (range 257 to 961). The patients were categorised as normoglycaemic (n=226, 53%), or as having impaired fasting glucose (n=118, 28%) or diabetes (n=82, 19%). RESULTS: The maximum percentage coronary atheroma area at baseline was greater in diabeticpatients (73.33+/-8.86%) than in those with normoglycaemia (69.08+/-10.43%; p=0.001) and impaired fasting glucose (69.32+/-9.59%; p=0.0031). In averaged IVUS measurements of the 30-mm target segment(n=332 participants), change in percentage atheroma area during follow-up was also greater in the diabetes (1.86+/-3.90%) than in other groups (0.28+/-3.32% and 0.56+/-2.96%,p=0.0047 global). FBG correlated with maximum percentage atheroma area at baseline (r=0.17; p=0.0003). HbA1c also correlated with maximum percentage atheroma area at baseline (r=0.26; p=0.0001) and with change in maximum plaque area (r=0.16; p=0.016). A similar pattern of results occurred with plaque volume. The relationships between diabetes or HbA1c and both IVUS measurements of plaque burden and remodelling persisted after adjustment. CONCLUSIONS/ INTERPRETATION: Fasting blood glucose, HbA1c and the presence of diabetes are associated with the severity and progression of coronary atherosclerosis. These observations support the hypothesis that better glycaemic control may favourably influence CAD in patients with abnormal glucose tolerance or diabetes.
Authors: G S Mintz; S E Nissen; W D Anderson; S R Bailey; R Erbel; P J Fitzgerald; F J Pinto; K Rosenfield; R J Siegel; E M Tuzcu; P G Yock Journal: J Am Coll Cardiol Date: 2001-04 Impact factor: 24.094
Authors: I De Scheerder; F De Man; M C Herregods; K Wilczek; L Barrios; E Raymenants; W Desmet; H De Geest; J Piessens Journal: Am Heart J Date: 1994-02 Impact factor: 4.749
Authors: Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Reda Ibrahim; Marc-André Lavoie; Michel LeMay; Eric Cohen; Sylvie Levesque; Pierre-Frédéric Keller; Therese Heinonen; Marie-Claude Guertin Journal: Am J Cardiol Date: 2006-05-03 Impact factor: 2.778
Authors: Stephen J Nicholls; E Murat Tuzcu; Tim Crowe; Ilke Sipahi; Paul Schoenhagen; Samir Kapadia; Stanley L Hazen; Chuan-Chuan Wun; Michele Norton; Fady Ntanios; Steven E Nissen Journal: J Am Coll Cardiol Date: 2006-04-24 Impact factor: 24.094
Authors: Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Todd J Anderson; Olivier Bertrand; Francois Reeves; Lawrence M Title; Fernando Alfonso; Erick Schampaert; Alita Hassan; Richard McLain; Milton L Pressler; Reda Ibrahim; Jacques Lespérance; John Blue; Therese Heinonen; Josep Rodés-Cabau Journal: Circulation Date: 2004-11-08 Impact factor: 29.690
Authors: Jakob R Larsen; Taro Tsunoda; E Murat Tuzcu; Paul Schoenhagen; Magne Brekke; Harald Arnesen; Kristian F Hanssen; Steven E Nissen; Knut Dahl-Jorgensen Journal: Diab Vasc Dis Res Date: 2007-03 Impact factor: 3.291
Authors: Clemens von Birgelen; Marc Hartmann; Gary S Mintz; K Gert van Houwelingen; Nadine Deppermann; Axel Schmermund; Dirk Böse; Holger Eggebrecht; Till Neumann; Mario Gössl; Heinrich Wieneke; Raimund Erbel Journal: Circulation Date: 2004-09-13 Impact factor: 29.690
Authors: R Kornowski; G S Mintz; A J Lansky; M K Hong; K M Kent; A D Pichard; L F Satler; J J Popma; T A Bucher; M B Leon Journal: Am J Cardiol Date: 1998-06-01 Impact factor: 2.778
Authors: Saad Albugami; Fahad Almehmadi; Ziad M Bukhari; Mohammed S Alqarni; Abdulkarim W Abukhodair; Malak A BinShihon; Faisal Al-Husayni; Razan A Alhazzani; Samah A AlMatrafi; Khalid Makki Journal: Cureus Date: 2020-10-31